Showing 6,601 - 6,620 results of 6,648 for search '(( significant decrease decrease ) OR ( significant associations decrease ))~', query time: 0.39s Refine Results
  1. 6601

    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  2. 6602

    Table 2_Determining the efficacy and safety of acupuncture for the treatment of menstrual migraine: an updated systematic review and meta-analysis.docx by Qiqi Wu (4895728)

    Published 2025
    “…Compared with control interventions, acupuncture significantly reduced VAS scores, decreased the frequency and duration of migraine attacks, and improved response rates, as well as HIT-6 and MHI scores. …”
  3. 6603

    Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  4. 6604

    Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  5. 6605

    Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  6. 6606

    Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  7. 6607

    Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  8. 6608

    Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  9. 6609

    Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  10. 6610

    Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, the combined treatment was associated with an increased incidence of total/grade 3–5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. …”
  11. 6611

    Supporting Data for "Managing NPO-Funder Relations for Financial Sustainability: Insights from Social Service Nonprofits in China" by Shiqi Peng (11134716)

    Published 2025
    “…Results found that greater reliance on a dominant funder was significantly associated with lower revenue generation (β = -0.5, p < 0.05), reduced surplus retention (β =-0.7, p < 0.001), and decreased operational efficiency (β = -0.0, p < 0.001). …”
  12. 6612

    Table1_CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.DOCX by Cataldo Martucci (3117069)

    Published 2024
    “…In a murine house dust mite (HDM) model of asthma exacerbated by influenza virus A (IAV) (H3N3), CHF6297 (0.1 mg/kg, i.n.) significantly decreased airway neutrophilia compared to vehicle-treated IAV/HDM-challenged mice. …”
  13. 6613

    Image1_Myeloid-derived growth factor promotes M2 macrophage polarization and attenuates Sjögren’s syndrome via suppression of the CX3CL1/CX3CR1 axis.tif by Zi Yang (276531)

    Published 2024
    “…The gene expression levels of cytokines and chemokines, including Ccl12, Ccl3, Il1r1, Ccr2, Cx3cr1, Il7, Mmp2, Mmp14, Il1b, and Il7, significantly decreased after treatment with MYDGF, as determined by RNA sequencing. …”
  14. 6614

    Table1_Myeloid-derived growth factor promotes M2 macrophage polarization and attenuates Sjögren’s syndrome via suppression of the CX3CL1/CX3CR1 axis.docx by Zi Yang (276531)

    Published 2024
    “…The gene expression levels of cytokines and chemokines, including Ccl12, Ccl3, Il1r1, Ccr2, Cx3cr1, Il7, Mmp2, Mmp14, Il1b, and Il7, significantly decreased after treatment with MYDGF, as determined by RNA sequencing. …”
  15. 6615

    Table 1_Combined inhibition of dopamine D1/D2 receptors induces cognitive and emotional dysfunction through oxidative stress and dopaminergic neuron damage.xls by Xue Li (285380)

    Published 2025
    “…</p>Results<p>Low-dose co-DR1/2I significantly increased MAO-B and ROS levels (p < 0.01) and decreased SOD activity (p < 0.01) in the substantia nigra, striatum, and hippocampus. …”
  16. 6616

    Lomie district map. by Arnauld Efon-Ekangouo (15295634)

    Published 2024
    “…The prevalence trend slightly decreased between 1987 and 2010 (~8%) and remained unchanged since 2010 (<i>p-value</i> = 0.05). …”
  17. 6617

    Data Sheet 4_Combined inhibition of dopamine D1/D2 receptors induces cognitive and emotional dysfunction through oxidative stress and dopaminergic neuron damage.zip by Xue Li (285380)

    Published 2025
    “…</p>Results<p>Low-dose co-DR1/2I significantly increased MAO-B and ROS levels (p < 0.01) and decreased SOD activity (p < 0.01) in the substantia nigra, striatum, and hippocampus. …”
  18. 6618

    Table_1_Hyperthyroidism, hypothyroidism, thyroid stimulating hormone, and dementia risk: results from the NHANES 2011–2012 and Mendelian randomization analysis.DOCX by Xixi Sheng (19932165)

    Published 2024
    “…This strategy has the potential to significantly contribute to the prevention and deceleration of dementia progression.…”
  19. 6619

    Data Sheet 1_Combined inhibition of dopamine D1/D2 receptors induces cognitive and emotional dysfunction through oxidative stress and dopaminergic neuron damage.zip by Xue Li (285380)

    Published 2025
    “…</p>Results<p>Low-dose co-DR1/2I significantly increased MAO-B and ROS levels (p < 0.01) and decreased SOD activity (p < 0.01) in the substantia nigra, striatum, and hippocampus. …”
  20. 6620

    Data Sheet 3_Combined inhibition of dopamine D1/D2 receptors induces cognitive and emotional dysfunction through oxidative stress and dopaminergic neuron damage.zip by Xue Li (285380)

    Published 2025
    “…</p>Results<p>Low-dose co-DR1/2I significantly increased MAO-B and ROS levels (p < 0.01) and decreased SOD activity (p < 0.01) in the substantia nigra, striatum, and hippocampus. …”